Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Semin Cancer Biol. 2019 Dec 19;65:28–37. doi: 10.1016/j.semcancer.2019.12.005

Figure 1:

Figure 1:

Current landscape for FDA-approved immune checkpoint inhibitor clinical trials. Using clinicaltrials.gov/, clinical trials (interventional studies) with status “Not yet recruiting”, “Recruiting”, “Enrolling by invitation” and “Active, not recruiting” were included in the figure.